Recently opposed patents at EPO
These are the recently opposed patents at EPO. This will help you to understand the market dynamics and the potential opportunities.
| Patent Number | Patent Title | Company | Recent Opposition Date | Recent Opposition By | Activity Alert |
|---|---|---|---|---|---|
| EP3542790 | NA | NA |
13 Jun, 2024
|
KRAUS & LEDERER PARTGMBB
(and 1 more)
| |
| EP3362061 | SUGLINGSNAHRUNG MIT MILCHFETT ZUR FRDERUNG DES GESUNDEN WACHSTUMS INFANT FORMULA WITH MILK FAT FOR PROMOTING HEALTHY GROWTH FORMULE POUR NOURRISSON AVEC MA- TIRE GRASSE DU LAIT FAVORISANT UNE CROISSANCE SAINE | NUTRICIA |
05 Jun, 2024
|
SOCIT DES PRODUITS NESTL
| |
| EP3866615 | NAHRUNGSERGNZUNG ZUR BEHAND- LUNG VON DYSBIOSE DIETARY SUPPLEMENT FOR TREATING DYSBIOSIS COMPLMENT ALIMENTAIRE POUR LE TRAITEMENT DE LA DYSBIOSE | FREEDOM HEALTH |
30 May, 2024
|
NUTRICIA
| |
| EP3723742 | VERWENDUNG VON FLUOROETHYLNOR- MEMANTIN ZUR VORBEUGUNG UND BE- HANDLUNG VON ANGSTZUSTNDEN USE OF FLUOROETHYLNORMEMANTINE FOR THE PREVENTION AND TREATMENT OF ANXIETY UTILISATION DE LA FLUOROETHYLNOR- MEMANTINE POUR LA PREVENTION ET LE TRAITEMENT DE L'ANXIETE | REST THERAPEUTICS |
24 May, 2024
|
BELHADJ TAHAR HAFID
| |
| EP3574907 | EIN NK1/NK3-REZEPTORANTAGONIST ZUR BEHANDLUNG VON GESCHLECHTS- HORMONABHNGIGEN ERKRANKUNGEN A DUAL NK-1/NK-3 RECEPTOR ANTAGO- NIST FOR THE TREATMENT OF SEX- HOR- MONE-DEPENDENT DISEASES UN ANTAGONISTE DES RCEPTEURS NK1/NK3 DESTIN AU TRAITEMENT DE MALADIES DPENDANTES DES HOR- MONES SEXUELLES | KANDY THERAPEUTICS |
23 May, 2024
|
AERA
| |
| EP4051251 | STABILE INJIZIERBARE NORADRENALIN- LSUNGEN, DIE FREI VON ANTIOXIDANTI- EN SIND STABLE, INJECTABLE NORADRENALINE SOLUTIONS FREE OF ANTIOXIDANTS SOLUTIONS INJECTABLES STABLES DE NORADRNALINE EXEMPTES D' ANTIOXY- DANTS | SINTETICA |
17 May, 2024
|
ZINNER
| |
| EP3352757 | VERABREICHUNG VON DEUTERIERTEN CF- TR-POTENZIATOREN ADMINISTRATION OF DEUTERATED CFTR POTENTIATORS ADMINISTRATION D'AGENTS DE POTEN- TIALISATION DE CFTR MODIFIS AU DEU- TRIUM | VERTEX PHARMACEUTICALS EUROPE |
16 May, 2024
|
GENERICS UK
| |
| EP3735217 | ZUBEREITUNG ENTHALTEND TENSIDEN, KATIONISCHE POLYMEREN UND EIN PFLANZENL COMPOSITION COMPRISING SURFAC- TANTS, CATIONIC POLYMERS AND A PLANT OIL COMPOSITION COMPRENANT DES TEN- SIOACTIFS, DES POLYMRES CATIO- NIQUES ET UNE HUILE VGTALE | LOREAL |
08 May, 2024
|
THE PROCTER & GAMBLE
(and 1 more)
| |
| EP3145504 | TRANSDERMALES ABGABESYSTEM MIT EI- NEM SCHNITTSTELLENMEDIATOR TRANSDERMAL DELIVERY SYSTEM IN- CLUDING AN INTERFACE MEDIATOR SYSTME D'ADMINISTRATION TRANSDER- MIQUE COMPRENANT UN MDIATEUR D'INTERFACE | LTS LOHMANN THERAPIE SYSTEME |
25 Apr, 2024
|
FH SERVICES
| |
| EP3746111 | NA | NA |
19 Apr, 2024
|
HEXAL
(and 3 more)
| |
| EP3240522 | HAARFARBENSYSTEM MIT EINER INTELLI- GENTEN VORRICHTUNG HAIR COLOR SYSTEM USING A SMART DE- VICE SYSTME DE COLORATION DE CHEVEUX UTILISANT UN DISPOSITIF INTELLIGENT | LOREAL |
17 Apr, 2024
|
HENKEL
| |
| EP2838548B1 | Hla Class Ii Deficient Cells, Hla Class I Deficient Cells Capable Of Expressing Hla Class Ii Proteins, And Uses Thereof | UNIVERSITY OF WASHINGTON CENTER FOR COMMERCIALIZATION |
16 Apr, 2024
(Expiration: Mar, 2033)
|
PAGE
(and 1 more)
| |
| EP3883606B9 | Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody | JANSSEN BIOTECH INC |
12 Apr, 2024
(Expiration: Sep, 2039)
|
ACCORD HEALTHCARE
(and 4 more)
| |
| EP3432890 | ERZEUGNIS, INSBESONDERE NAHRUNGS- MITTELZUSATZ, FUTTERMITTEL, NAH- RUNGSMITTEL, PHARMAZEUTIKUM, KOS- METIKUM UND/ODER TIERFUTTERZU- SATZ, ZUR ZUFUHR ZUMINDES EINES AN EINEN VITAMIN-D-REZEPTOR BINDEN- DEN MOLEKLS, UND VERFAHREN ZU DESSEN HERSTELLUNG PRODUCT, IN PARTICULAR NUTRITIONAL SUPPLEMENT, ANIMAL FEED, FOOD- STUFF, DRUG, COSMETIC AND/OR ANI- MAL FEED SUPPLEMENT FOR SUPPLYING AT LEAST ONE MOLECULE THAT BONDS TO A VITAMIN D RECEPTOR, AND METHOD FOR THE PRODUCTION THERE- OF PRODUIT, NOTAMMENT COMPLMENT ALIMENTAIRE, ALIMENT POUR ANIMAUX, PRODUIT ALIMENTAIRE, PRODUIT PHAR- MACEUTIQUE, PRODUIT COSMTIQUE ET/OU ADDITIF D'ALIMENT POUR ANI- MAUX, DESTIN L'APPORT D'AU MOINS UNE MOLCULE SE LIANT AU RCEPTEUR DE LA VITAMINE D, ET PROCD DE FA- BRICATION ASSOCI | BTER |
12 Apr, 2024
|
HERBONIS ANIMAL HEALTH
| |
| EP3606522 | NEUARTIGE BEHANDLUNG VON MIT- OCHONDRIALEN ERKRANKUNGEN NOVEL TREATMENT OF MITOCHONDRIAL DISEASES NOUVEAU TRAITEMENT DE MALADIES MI- TOCHONDRIALES | KHONDRION |
10 Apr, 2024
|
SULFATEQ
| |
| EP3793533 | TABLETTENDOSIERUNGSFORM ZUR BUK- KALEN ABSORPTION VON WIRKSTOFFEN A TABLET DOSAGE FORM FOR BUCCAL ABSORPTION OF ACTIVE INGREDIENTS FORME POSOLOGIQUE DE COMPRIM POUR L'ABSORPTION BUCCALE D' INGR- DIENTS ACTIFS | FERTIN PHARMA |
05 Apr, 2024
|
NICOVENTURES TRADING
| |
| EP3501605 | MRNA-THERAPIE FR ARGININOSUCCI- NAT-SYNTHASE-MANGEL MRNA THERAPY FOR ARGININOSUCCI- NATE SYNTHETASE DEFICIENCY THRAPIE ARNM POUR DFICIENCE EN ARGININOSUCCINATE SYNTHTASE | TRANSLATE BIO |
28 Mar, 2024
|
AWA SWEDEN
| |
| EP3110449B1 | Medical Use Of A Dpp-4 Inhibitor | BOEHRINGER INGELHEIM |
28 Mar, 2024
|
GENERICS UK
(and 4 more)
| |
| EP4058148B1 | Dosing Regimen For Anti-Bcma Agents | NA |
15 Mar, 2024
|
STRAWMAN
| |
| EP3300743B1 | Methods Of Vaccine Administration | ZOETIS SERVICES |
13 Mar, 2024
|
BOEHRINGER INGELHEIM VETMEDICA
| |
| EP3463315B1 | Compositions And Methods Of Using Nintedanib For Treating Ocular Diseases With Abnormal Neovascularization | ADS THERAPEUTICS |
13 Mar, 2024
|
MARGARET DIXON
| |
| EP2913327B1 | Methylene Blue And Its Medical Use | PROVEPHARM LIFE SOLUTIONS |
07 Mar, 2024
|
AERA
(and 1 more)
| |
| EP3810201B9 | Gip/Glp1 Agonist Compositions | ELI LILLY |
07 Mar, 2024
|
GENERICS UK
(and 6 more)
| |
| EP3870213B1 | Stable Semaglutide Compositions And Uses Thereof | NOVO NORDISK |
07 Mar, 2024
|
GENERICS UK
| |
| EP3860590B1 | Methods For The Treatment Of Scleroderma | ARENA PHARMACEUTICALS |
07 Mar, 2024
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 1 more)
| |
| EP3525775B1 | Arginine And Its Use As A T Cell Modulator | INSTITUTE FOR RESEARCH IN BIOMEDICINE IRB |
07 Mar, 2024
(Expiration: Oct, 2037)
|
HAMPTON KNOWLES
(and 2 more)
| |
| EP3488857B9 | Compositions Of Glp-1 Peptides And Preparation Thereof | NOVO NORDISK |
07 Mar, 2024
(Expiration: Mar, 2033)
|
HEXAL
(and 4 more)
| |
| EP2691157B1 | Isopentyl Esters For The Use In Cosmetic, Dermatological, Or Pharmaceutical Compositions | EVONIK OPERATIONS |
07 Mar, 2024
|
KRAUS & LEDERER PARTGMBB
| |
| EP3509559B8 | Injectable Gels Comprising Cross-Linked Hyaluronic Acid And Hydroxyapatite, And Methods Of Manufacturing Thereof | ALLERGAN PHARMACEUTICALS |
07 Mar, 2024
|
MERZ PHARMA
| |
| EP3345604B1 | Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations | H LUNDBECK |
06 Mar, 2024
|
BIOGARAN
(and 1 more)
| |
| EP2283851B1 | Compositions And Methods For Promoting Hemostasis And Other Physiological Activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
06 Mar, 2024
|
EIP
| |
| EP3381438B1 | Composition For Injection Of Hyaluronic Acid, Containing Hyaluronic Acid Derivative And Dna Fraction, And Use Thereof | BMI KOREA |
06 Mar, 2024
|
MASTELLI
| |
| EP3090729B1 | Emulsion | VITUX GROUP |
06 Mar, 2024
|
SIRIO HEALTHCARE ANHUI
| |
| EP3291789B1 | Improved Color Depositing Shampoo | CELEB |
04 Mar, 2024
|
CLARIANT PRODUKTE DEUTSCHLAND
| |
| EP3466491B1 | Hair Treatment Method And Kit Thereof | WELLA OPERATIONS |
04 Mar, 2024
|
HENKEL
| |
| EP3619232B1 | Multikinase Inhibitors And Uses In Ocular Fibrosis | AIVIVA BIOPHARMA |
04 Mar, 2024
|
MARGARET DIXON
| |
| EP3536712B1 | Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9) | REGENERON PHARMACEUTICALS |
29 Feb, 2024
|
AMGEN
| |
| EP3897608B1 | Dietary Butyrate For Treating Or Preventing An Allergic Disorder | SOCIT DES PRODUITS NESTL |
29 Feb, 2024
|
NUTRICIA
| |
| EP2995315B1 | Compositions And Methods For Treating Hematologic Cancers Targeting The Sirp Alpha- Cd47 Interaction | UNIVERSITY HEALTH NETWORK |
22 Feb, 2024
|
LEEMING
| |
| EP3452175B1 | Gentle Cleansing Compositions With Makeup Removal Properties | LOREAL |
20 Feb, 2024
|
HENKEL
| |
| EP3651730B1 | New Composition For Straightening Hair | DI VISCO |
20 Feb, 2024
|
HENKEL
| |
| EP3666797B1 | Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) | AMGEN INC |
19 Feb, 2024
(Expiration: Aug, 2028)
|
REGENERON PHARMACEUTICALS
(and 1 more)
| |
| EP2687202B1 | Subcutaneous Anti-Her2 Antibody Formulation | F HOFFMANN LA ROCHE |
12 Feb, 2024
|
ACCORD HEALTHCARE
| |
| EP3485890B1 | Treatment Of Metabolic Disorders In Canine Animals | BOEHRINGER INGELHEIM VETMEDICA |
09 Feb, 2024
|
CEVA SANTE ANIMALE
| |
| EP2508188B1 | Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate | ASTRAZENECA |
09 Feb, 2024
|
GENERICS UK
(and 4 more)
| |
| EP3263110B1 | Solid Preparation | TAKEDA PHARMACEUTICAL |
08 Feb, 2024
|
SANDOZ
| |
| EP3250681B1 | Compositions And Methods For T Cell Delivery Of Therapeutic Molecules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
05 Feb, 2024
|
JAMES POOLE
| |
| EP3613421B1 | Dry Powder Inhaler And Methods Of Use | VECTURA |
02 Feb, 2024
|
GENERICS UK
| |
| EP3240842B1 | Novel Film Coating Composition | IDEAL CURES PVT |
01 Feb, 2024
|
KADOR & PARTNER PARTG MBB
| |
| EP4093367B1 | Isotropic Concentrate And Wash Compositions | UNILEVER |
30 Jan, 2024
|
HENKEL
| |
| EP4023755B1 | Artificial Nucleic Acid Molecules For Improved Protein Expression | CUREVAC SE |
26 Jan, 2024
(Expiration: Dec, 2035)
|
COOLEY UK
(and 3 more)
| |
| EP4090310B1 | Hair Treatment Composition | UNILEVER |
26 Jan, 2024
|
DALLI WERKE
| |
| EP4021929B1 | Ham15-52 Analogues With Improved Amylin Receptor (Hamy3R) Potency | GUBRA APS |
26 Jan, 2024
|
STRAWMAN
| |
| EP3368047B1 | Synthetic Composition And Method For Modulating Emotion And Mood Disorders | GLYCOM AS |
25 Jan, 2024
(Expiration: Oct, 2036)
|
WEICKMANN & WEICKMANN PARTMBB
| |
| EP3892295B1 | Individualized Vaccines For Cancer | TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH |
25 Jan, 2024
(Expiration: May, 2032)
|
WITHERS & ROGERS LLPJONES NICHOLASWRIGHT HOWARD WALLIN NICHOLAS
| |
| EP3697392B1 | Tablets Comprising Tamsulosin And Solifenacin | SYNTHON BV |
23 Jan, 2024
(Expiration: Oct, 2038)
|
ADALVO
| |
| EP3363811B1 | Method For Producing Fusion Protein Having Igg Fc Domain | ALTEOGEN INC |
18 Jan, 2024
(Expiration: Oct, 2036)
|
BOULT WADE TENNANT
(and 3 more)
| |
| EP3769781B1 | Stable Anti-Ifnar1 Formulation | ASTRAZENECA AB |
18 Jan, 2024
(Expiration: Aug, 2036)
|
MAIWALD
| |
| EP3233204B1 | Composition For Enhancing Hair Fiber Properties | PROCTER AND GAMBLE CO |
16 Jan, 2024
(Expiration: Dec, 2035)
|
HENKEL
| |
| EP3886820B8 | Capsule Formulations | CHEMOCENTRYX INC |
12 Jan, 2024
(Expiration: Nov, 2039)
|
LEK PHARMACEUTICALS DD
(and 1 more)
| |
| EP2858496B9 | Oils With Anti-Inflammatory Activity Containing Natural Specialized Proresolving Mediators And Their Precursors | SOLUTEX NA LLC |
11 Jan, 2024
(Expiration: May, 2033)
|
EPAX NORWAY
| |
| EP3970513B1 | Non-Tobacco Oral Nicotine Pouch Composition | PHILIP MORRIS PRODUCTS SA |
11 Jan, 2024
(Expiration: Nov, 2040)
|
NICOVENTURES TRADING
| |
| EP3648796B1 | Dispersion For An Aqueous Spray Formulation With Controlled Mechanical Degradation | GREENA BV |
05 Jan, 2024
(Expiration: Jul, 2037)
|
STRAWMAN
| |
| EP3930670B1 | Biobased Pearlescent Waxes | BASF SE |
04 Jan, 2024
(Expiration: Feb, 2040)
|
CLARIANT PRODUKTE DEUTSCHLAND
(and 1 more)
| |
| EP3618875B1 | Combination Therapy | NOVARTIS AG |
04 Jan, 2024
(Expiration: Apr, 2038)
|
STADA ARZNEIMITTEL
| |
| EP3724319B1 | Methods For Obtaining Muscle Derived Cells | INNOVACELL AG |
03 Jan, 2024
(Expiration: Dec, 2038)
|
OLIGSCHLGER
| |
| EP3954690B1 | Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide | ACERTA PHARMA BV |
29 Dec, 2023
(Expiration: Jul, 2036)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3439647B1 | Method For Reducing Or Preventing Global Developmental Delay In Children | NUTRICIA NV |
21 Dec, 2023
(Expiration: Apr, 2036)
|
SOCIT DES PRODUITS NESTL
| |
| EP3416658B1 | Human Functional Corneal Endothelial Cell And Application Thereof | KYOTO PREFECTURAL PUBLIC UNIV CORP |
20 Dec, 2023
(Expiration: Feb, 2037)
|
VO
| |
| EP2658520B1 | Leave-In Conditioning Composition For Hair | KAO GERMANY GMBH |
18 Dec, 2023
(Expiration: Dec, 2031)
|
HENKEL
| |
| EP3512505B1 | Vildagliptin Pharmaceutical Compositions | GALENICUM HEALTH SL |
15 Dec, 2023
(Expiration: Sep, 2037)
|
ELKINGTON AND FIFE
(and 1 more)
| |
| EP3290043B1 | Enzyme-Treated Milk Product, Method For Producing Same, Composition, And Product | SAISEI PHARMA CO LTD |
15 Dec, 2023
(Expiration: May, 2036)
|
NUTRICIA
| |
| EP3645553B1 | Tropism-Modified Recombinant Viral Particles And Uses Thereof For The Targeted Introduction Of Genetic Material Into Human Cells | REGENERON PHARMACEUTICALS INC |
15 Dec, 2023
(Expiration: Jun, 2038)
|
STRAWMAN
(and 1 more)
| |
| EP3598967B1 | Personal Cleansing Compositions, Methods And Uses | PROCTER AND GAMBLE CO |
15 Dec, 2023
(Expiration: Jul, 2038)
|
UNILEVER UNILEVER
| |
| EP3179986B1 | Dry Powder Formulations For Inhalation | VECTURA INC |
14 Dec, 2023
(Expiration: Jul, 2035)
|
GENERICS UK
| |
| EP3727599B8 | Composition For Dyeing Keratin Fibers Containing A Combination Of A P-Phenylene Derivative And 2,7-Naphthalenediol And Use Thereof For Reducing A Yellow Tinge In A Hairstyle | LABORATOIRE BIOSTHETIQUE KOSMETIK & CO KG GMBH |
14 Dec, 2023
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP4070788B1 | Pharmaceutical Formulations | GILEAD SCIENCES INC |
11 Dec, 2023
(Expiration: Jun, 2036)
|
ZENTIVA
| |
| EP3294283B1 | Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure | NOVARTIS AG |
08 Dec, 2023
(Expiration: May, 2036)
|
ZENTIVA
(and 14 more)
| |
| EP3042669B1 | Antitumor Agent And Antitumor Effect Enhancer | TAIHO PHARMACEUTICAL CO LTD |
07 Dec, 2023
(Expiration: Sep, 2034)
|
GENERICS UK
(and 1 more)
| |
| EP3402573B1 | Composition Containing Amino Acids | INDIVIDUAL |
01 Dec, 2023
(Expiration: Jan, 2037)
|
ARLA FOODS AMBA
(and 1 more)
| |
| EP3000467B1 | Treatment Regimen Utilizing Neratinib For Breast Cancer | WYETH LLC |
01 Dec, 2023
(Expiration: Mar, 2030)
|
GENERICS UK
(and 2 more)
| |
| EP2981272B1 | Microporous Zirconium Silicate And Diuretics For The Reduction Of Potassium And Treatment Of Chronic Kidney And/Or Chronic Heart Disease | ZS PHARMA INC |
01 Dec, 2023
(Expiration: Apr, 2034)
|
GENERICS UK
(and 1 more)
| |
| EP4066819B1 | Small Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
01 Dec, 2023
(Expiration: Aug, 2031)
|
JG OPPOSITIONS
(and 3 more)
| |
| EP3686211B1 | Process For Efficient Purification Of Neutral Human Milk Oligosaccharides (Hmos) From Microbial Fermentation | CHR HANSEN HMO GMBH |
30 Nov, 2023
(Expiration: Dec, 2034)
|
FRIESLANDCAMPINA NEDERLAND
(and 1 more)
| |
| EP3680249B1 | Process For Efficient Purification Of Neutral Human Milk Oligosaccharides (Hmos) From Microbial Fermentation | CHR HANSEN HMO GMBH |
30 Nov, 2023
(Expiration: Dec, 2034)
|
GREAVES BREWSTER
(and 1 more)
| |
| EP4070787B1 | Pharmaceutical Formulations | GILEAD SCIENCES INC |
29 Nov, 2023
(Expiration: Jun, 2036)
|
ZENTIVA
| |
| EP3880160B1 | Dentifrice Containing Sodium Bicarbonate And Stannous Fluoride | COLGATE PALMOLIVE CO |
27 Nov, 2023
(Expiration: Dec, 2039)
|
HALEON UK
| |
| EP3302507B1 | Diagnostic Methods For T Cell Therapy | US DEPARTMENT OF HEALTH AND HUMAN SERVICES |
22 Nov, 2023
(Expiration: May, 2036)
|
BOULT WADE TENNANT
| |
| EP3395383B1 | Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo | REGEN LAB SA |
22 Nov, 2023
(Expiration: Aug, 2027)
|
ESTAR
| |
| EP3811943B1 | Compound For Use In The Treatment Of Ocular Disorders | AERIE PHARMACEUTICALS INC |
22 Nov, 2023
(Expiration: Mar, 2034)
|
GENERICS UK
(and 2 more)
| |
| EP3880197B1 | Methods Of Treatment For Cystic Fibrosis | VERTEX PHARMACEUTICALS INC |
22 Nov, 2023
(Expiration: Nov, 2039)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP3393510B1 | Zika Virus Vaccine | VALNEVA AUSTRIA GMBH |
21 Nov, 2023
(Expiration: Dec, 2036)
|
MAIWALD
| |
| EP3534939B1 | Vaccine Against Porcine Parvovirus And Porcine Reproductive And Respiratory Syndrome Virus And Methods Of Production Thereof | BOEHRINGER INGELHEIM VETMEDICA GMBH |
21 Nov, 2023
(Expiration: Nov, 2037)
|
ZOETIS SERVICES
| |
| EP2575744B1 | Skin Treatment Composition | UNILEVER GLOBAL IP LTD |
27 Oct, 2023
(Expiration: May, 2031)
|
BEIERSDORF
| |
| EP4010082B1 | Multispecific Anti-Tcr Delta Variable 1 Antibodies | GAMMADELTA THERAPEUTICS LTD |
25 Oct, 2023
(Expiration: Aug, 2041)
|
MARGARET DIXON
| |
| EP3551160B1 | Flexible Solid Cosmetic Composition Comprising Sulfonate Anionic Surfactants, Fatty Esters And Fatty Alcohols, And Cosmetic Treatment Method | LOREAL SA |
23 Oct, 2023
(Expiration: Nov, 2037)
|
HENKEL
| |
| EP3805248B1 | Process For Concentration Of Antibodies And Therapeutic Products Thereof | NOVARTIS AG |
18 Oct, 2023
(Expiration: Sep, 2025)
|
KILBURN & STRODE
(and 1 more)
| |
| EP3122426B1 | Method Of Treating Cancer Using Selective Estrogen Receptor Modulators | DUKE UNIVERSITY |
18 Oct, 2023
(Expiration: Mar, 2035)
|
SANDOZ
(and 1 more)
| |
| EP3362055B1 | Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
17 Oct, 2023
(Expiration: Oct, 2036)
|
GENERICS UK
(and 1 more)
| |
| EP2482812B1 | Therapeutic Uses Of Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
11 Oct, 2023
(Expiration: Oct, 2030)
|
GALENICUM
(and 2 more)
|